LOGIN  |  REGISTER
Terns Pharmaceuticals

List of Pharmaceutical Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 857.20
12.93 1.53
3.01M
899.32M
US$ 770.900B
US$ 154.99
-1.16 -0.74
7.72M
2.41B
US$ 373.530B
US$ 196.25
17.05 9.51
7.20M
1.77B
US$ 347.360B
US$ 82.20
4.33 5.56
8.66M
3.37B
US$ 277.010B
US$ 74.80
1.22 1.66
5.73M
3.10B
US$ 231.880B
US$ 40.86
-0.20 -0.49
171,214
5.52B
US$ 225.550B
US$ 106.61
1.18 1.12
1.18M
2.00B
US$ 213.220B
US$ 83.29
0.28 0.34
22.81M
2.53B
US$ 210.720B
US$ 292.80
1.64 0.56
1.89M
537.53M
US$ 157.390B
US$ 25.56
0.03 0.12
35.45M
5.67B
US$ 144.930B
US$ 53.95
-0.55 -1.01
2.05M
2.51B
US$ 135.410B
US$ 105.25
1.17 1.12
8.25M
1.25B
US$ 131.560B
US$ 54.43
0.53 0.98
10.39M
2.03B
US$ 110.490B
US$ 36.61
0.44 1.22
4.31M
2.04B
US$ 74.680B
US$ 156.48
-1.04 -0.66
6.56M
451.16M
US$ 70.600B
US$ 13.90
0.36 2.66
1.68M
3.17B
US$ 44.060B
US$ 5.71
0.06 1.06
226,886
3.93B
US$ 22.440B
US$ 136.57
-0.76 -0.55
1.24M
145.72M
US$ 19.900B
US$ 16.57
0.32 1.97
16.94M
1.13B
US$ 18.720B
US$ 9.69
-0.08 -0.82
3,438
1.79B
US$ 17.350B
US$ 10.86
0.06 0.56
7.51M
1.19B
US$ 12.920B
US$ 63.48
0.00 0.00
0
181.51M
US$ 11.520B
US$ 13.56
-0.04 -0.29
3.10M
833.08M
US$ 11.300B
US$ 11.06
1.36 14.02
44.71M
864.15M
US$ 9.560B
US$ 28.90
0.00 0.00
0
330.84M
US$ 9.560B
US$ 17.35
0.16 0.93
4,575
334.72M
US$ 5.810B
US$ 11.32
0.07 0.62
3.36M
494.35M
US$ 5.600B
US$ 15.48
0.20 1.31
3.37M
257.54M
US$ 3.990B
US$ 49.44
-2.38 -4.59
752,174
77.13M
US$ 3.810B
US$ 24.14
-0.35 -1.43
1.17M
136.43M
US$ 3.290B
US$ 13.72
-0.08 -0.58
35,753
170.94M
US$ 2.350B
US$ 6.36
0.20 3.25
2.48M
367.80M
US$ 2.340B
US$ 39.75
0.64 1.64
479,959
55.22M
US$ 2.190B
US$ 7.38
0.06 0.82
569,066
257.44M
US$ 1.900B
US$ 30.75
-0.27 -0.87
969,023
48.08M
US$ 1.480B
US$ 10.83
1.00 10.17
912,388
124.63M
US$ 1.350B
US$ 58.73
-0.19 -0.32
119,043
21.02M
US$ 1.230B
US$ 26.44
1.00 3.93
647,061
46.17M
US$ 1.220B
US$ 30.57
0.15 0.49
341,247
35.61M
US$ 1.090B
US$ 29.71
0.05 0.17
210,567
32.25M
US$ 958.150M
US$ 14.79
0.05 0.34
468,621
63.32M
US$ 936.500M
US$ 30.98
0.00 0.00
0
29.67M
US$ 919.180M
US$ 15.30
0.45 3.03
445,658
58.13M
US$ 889.390M
US$ 8.54
-0.07 -0.81
1.21M
96.36M
US$ 822.910M
US$ 19.55
-0.19 -0.96
229,526
41.57M
US$ 812.690M
C$ 5.64
-0.01 -0.18
28,449
100.80M
C$ 568.510M
US$ 0.50
-0.03 -5.66
966,039
1.07B
US$ 535.000M
US$ 25.82
0.05 0.19
347,211
20.34M
US$ 525.180M
US$ 8.75
-0.97 -9.98
1.87M
54.18M
US$ 474.080M
US$ 3.65
-0.05 -1.35
782,751
125.73M
US$ 458.910M
US$ 7.75
-0.03 -0.39
319,502
57.49M
US$ 445.550M
US$ 8.12
-0.16 -1.93
158,091
53.31M
US$ 432.880M
US$ 8.28
0.62 8.09
1.71M
42.19M
US$ 349.330M
C$ 12.72
-0.18 -1.40
16,887
25.59M
C$ 325.500M
US$ 2.00
0.08 4.17
3.55M
160.03M
US$ 320.060M
US$ 6.00
-0.09 -1.48
140,530
37.03M
US$ 222.180M
C$ 4.20
0.00 0.00
200
31.79M
C$ 133.520M
C$ 11.10
0.10 0.91
3,501
11.37M
C$ 126.210M
US$ 0.12
-0.0007 -0.58
13.26M
979.95M
US$ 117.590M
US$ 1.02
0.00 0.00
0
112.82M
US$ 115.080M
US$ 1.18
-0.04 -3.28
397,302
81.60M
US$ 96.290M
US$ 1.91
0.16 9.03
108,965
45.98M
US$ 87.730M
US$ 0.56
0.02 3.45
3.29M
146.38M
US$ 81.970M
US$ 5.14
-0.10 -1.91
29,246
14.89M
US$ 76.530M
C$ 3.00
-0.09 -2.91
46,375
24.65M
C$ 73.950M
US$ 4.82
-0.33 -6.41
305,888
14.04M
US$ 67.670M
US$ 1.90
0.05 2.70
273,249
32.32M
US$ 61.410M
US$ 5.85
-0.15 -2.50
12,419
10.06M
US$ 58.850M
US$ 0.35
0.00 0.00
1.03M
166.19M
US$ 58.830M
US$ 3.70
-0.05 -1.33
4,369
13.01M
US$ 48.140M
US$ 1.07
-0.05 -4.46
575,261
37.94M
US$ 40.600M
US$ 1.77
-0.01 -0.56
37,512
17.64M
US$ 31.220M
US$ 0.93
-0.05 -4.66
155,048
32.74M
US$ 30.450M
US$ 0.84
0.01 1.20
94,761
33.10M
US$ 27.740M
US$ 3.15
0.00 0.00
3,132
8.75M
US$ 27.520M
C$ 0.17
-0.02 -8.33
21,570
147.75M
C$ 24.380M
US$ 0.77
0.00 0.00
29,554
31.04M
US$ 23.870M
US$ 1.26
0.01 0.80
44,093
17.18M
US$ 21.650M
US$ 1.14
-0.02 -1.72
135,541
16.56M
US$ 18.880M
C$ 0.20
-0.02 -7.14
43,280
94.66M
C$ 18.460M
US$ 0.94
0.009 0.96
136,824
18.18M
US$ 17.160M
US$ 0.61
-0.01 -1.66
402,642
23.26M
US$ 14.170M
US$ 4.63
0.05 1.09
34,311
2.86M
US$ 13.240M
US$ 1.00
0.13 14.29
4,651
12.96M
US$ 12.960M
US$ 1.02
-0.01 -0.97
29,183
11.53M
US$ 11.760M
US$ 0.64
-0.03 -4.63
72,572
17.03M
US$ 10.880M
C$ 0.56
-0.01 -1.75
500
19.12M
C$ 10.710M
US$ 0.42
0.09 28.31
177.61M
23.87M
US$ 9.950M
US$ 1.15
-0.03 -2.54
71,449
7.75M
US$ 8.910M
US$ 1.30
-0.03 -2.26
1,953
6.18M
US$ 8.030M
US$ 5.25
-0.12 -2.23
13,659
1.49M
US$ 7.820M
C$ 0.72
0.00 0.00
0
10.44M
C$ 7.520M
US$ 2.45
-0.07 -2.59
123,584
2.71M
US$ 6.630M
C$ 0.05
0.00 0.00
0
98.66M
C$ 4.440M
US$ 3.22
0.00 0.00
0
1.28M
US$ 4.120M
US$ 0.20
-0.01 -6.02
680,514
19.25M
US$ 3.910M
C$ 0.02
0.00 0.00
4,916
171.56M
C$ 3.430M
US$ 2.50
0.01 0.50
13,245
1.34M
US$ 3.350M
US$ 3.68
0.86 30.50
43.69M
874,862
US$ 3.220M
US$ 0.68
-0.02 -2.82
66,206
3.66M
US$ 2.490M
US$ 0.38
-0.004 -1.05
104,507
4.06M
US$ 1.530M
US$ 0.14
-0.15 -52.56
31.85M
10.01M
US$ 1.390M
C$ 0.005
0.00 0.00
0
132.63M
C$ 663K
C$ 0.005
0.00 0.00
0
109.79M
C$ 549K
US$ 0.16
-0.01 -6.06
1.76M
2.10M
US$ 326K
US$ 0.00
0.00 0.00
0
13.96M
US$ -
US$ 0.00
0.00 0.00
0
64.47M
US$ -

Latest Pharmaceutical Stock News


HUTCHMED to Announce 2024 Final Results

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2024 on Wednesday, March 19, 2025 at 7:00 am Eastern Daylight Time (EDT) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted... Read more


Teva Pharmaceutical to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and...

TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live webcast at 8 am E.T. on Monday, February 24, 2025. During the conference call, Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer, and external IBD key opinion leaders (KOLs) will discuss new data presented for duvakitug (anti-TL1A) positive Phase 2b results at... Read more


Supernus Pharmaceuticals Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo SPN-820 was well-tolerated with few adverse events, consistent with previously reported studies ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central... Read more


Voyageur Pharmaceuticals Advances MRI Drug Development Using Next Generation Endohedral Fullerenes

Calgary, Alberta, Canada – February 18, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company") is pleased to announce the launch of its next generation MRI contrast agent development program in collaboration with Applied Pharmaceutical Innovations (API) and Rain Cage Carbon Inc (RC). This program aims to create novel, high performance MRI contrast drug formulations utilizing advanced nanotechnology.  Under this... Read more


Medicure Announces Expansion of Its Pharmacy Business Through Signing of a Purchase Agreement for the Acquisition of Gateway Medical Pharmacy

WINNIPEG, MB / ACCESS Newswire / February 18, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH) (OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced that through its wholly-owned U.S. subsidiary, Medicure Pharma Inc., it has signed a definitive agreement on February 14, 2025 to acquire 100% of Gateway Medical Pharmacy Inc.... Read more


U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

If Approved, Lenacapavir Would Be the First and Only Twice-Yearly HIV Prevention Choice  FDA to Review Applications Under Priority Review, with a PDUFA Date of June 19, 2025  Gilead Also Recently Submitted Applications for Lenacapavir for PrEP to the European Medicines Agency That Will Be Reviewed Under Accelerated Assessment Review Timeline  FOSTER CITY, Calif. / Feb 18, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that... Read more


PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

DeepSolar brings new customer base in creation, including major utility-scale solar operators and independent power producers, while breaking into the residential solar market The Company remains committed to advancing its drug delivery technologies while broadening its growth potential TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the... Read more


Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and N...

Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen’s rare disease pipeline and leverages global expertise commercializing high-value, disease-modifying medicines for rare genetic diseases Pivotal Phase 3 EMPEROR study of zorevunersen on track to initiate in Q2 2025 with an anticipated readout in 2H 2027 Stoke to receive $165M upfront,... Read more


Cumberland Pharmaceuticals: Vibativ Receives Marketing Approval In China

Vibativ® is a life-saving antibiotic for pneumonia and serious skin infections Approval in China paves the way for launch in world's second-largest market NASHVILLE, Tenn. and SHANGHAI, Feb. 18, 2025 /PRNewswire/ -- Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) and SciClone Pharmaceuticals (Holdings) Limited ("SciClone Pharmaceuticals" or "SciClone") today announced the NMPA (National Medical Products Administration) approval of... Read more


Merck: WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications

WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union RAHWAY, N.J. / Feb 18, 2025 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), Merck’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, as monotherapy for: The treatment of adult patients with von Hippel-Lindau... Read more


Alvotech and Teva Pharmaceutical Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT06, Alvotech’s... Read more


ProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports

GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer products company, today announced the appointment of Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company’s expansion into consumer-centered health and wellness products. As COO, Hollenshead will focus on accelerating ProPhase Labs’ consumer-facing strategy, leveraging... Read more


PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY

Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W, and Y) Broad serogroup coverage in one vaccine reduces injections to help improve vaccination rates and help protect more US adolescents and young adults PHILADELPHIA / Feb 17, 2025 / Business Wire / GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) for... Read more


Bristol-Myers Squibb: New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment, clinical response was maintained in nearly half of patients for Psoriasis Area and Severity Index (PASI) 90 in the POETYK PSO long-term extension trial PRINCETON, N.J. / Feb 16, 2025 / Business Wire / Bristol Myers Squibb (NYSE:BMY) today announced new five-year results from... Read more


Zoetis Receives Conditional License from USDA for Avian Influenza Vaccine, H5N2 Subtype, Killed Virus

PARSIPPANY, N.J. / Feb 14, 2025 / Business Wire / Zoetis today announced that the U.S. Department of Agriculture (USDA), Center for Veterinary Biologics (CVB) has issued the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. The vaccine is labelled for use in chickens. The conditional license was granted on the demonstration of safety, purity, and reasonable expectation of efficacy based on serology data. Zoetis is committed to supporting... Read more


IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc...

IMFINZI reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone WILMINGTON, Del. / Feb 14, 2025 / Business Wire / Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab), administered perioperatively in combination with neoadjuvant chemotherapy, demonstrated improvements in event-free survival (EFS) and overall survival (OS) versus neoadjuvant... Read more


AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

Richard A. Gonzalez to retire from the board of directors effective July 1, 2025 NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation... Read more


Incannex Healthcare Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submission New OSA Clinical Advisory Board Announced; Appoints Dr. Alison Wimms, Representing ResMed NEW YORK and MELBOURNE, Australia, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported... Read more


Theratechnologies Resumes Distribution of EGRIFTA SV®

MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today announced that it has resumed distribution of EGRIFTA SV® (tesamorelin for injection), following correspondence from the U.S. Food and Drug Administration (FDA) that allows the... Read more


Elite Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2025 ended December 31, 2024 and Provides Conference Call Information

Conference Call Scheduled for Friday, February 14 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - February 13, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended December 31, 2024, which is the third quarter of the Company's fiscal year ending on March 31, 2025 ("Third... Read more


Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

First Major Technological Breakthrough in Hyaluronic Acid Dermal Fillers in a Decade; U.S. Launch Planned in Q2 2025 Launch Establishes Evolus as a Multi-Product Performance Beauty Company and Expands Addressable Market by 78% NEWPORT BEACH, Calif. / Feb 13, 2025 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that the U.S. Food and Drug Administration (FDA) has approved Evolysse™... Read more


Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer

TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) regardless of HRR mutation status TALZENNA + XTANDI improved median OS by almost 9 months in unselected patients (Cohort 1) and by 14 months in patients selected for HRR mutations (Cohort 2) versus standard of care XTANDI NEW... Read more


Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

PRINCETON, N.J. / Feb 13, 2025 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients with completely resected stage III-IV melanoma did not meet its primary endpoint of recurrence-free survival (RFS). The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab. “We are... Read more


Johnson & Johnson: New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody...

Published results reinforce the high-affinity binding and immunoselective properties of nipocalimab, which has been shown to reduce IgG levels by >75%, including autoantibodies, potentially without affecting other immune functions SPRING HOUSE, Pa., Feb. 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the publication of data detailing the differentiated molecular properties of nipocalimab, an investigational neonatal Fc receptor (FcRn)... Read more


Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024

Full year 2024 revenue of $6.4 billion, up 2% as-reported and 3% at constant currency Full year 2024 diluted earnings per share of $3.33 and non-GAAP Adjusted diluted earnings per share of $4.11 Full year 2024 Adjusted EBITDA of $1.96 billion inclusive of $81 million of IPR&D, representing a 30.6% Adjusted EBITDA margin Full year 2025 financial guidance ranges provided Full year revenue range of $6.125 billion - $6.325 billion, inclusive of an approximate $200... Read more


Zoetis Reports Fourth Quarter and Full Year 2024 Results

Reports Revenue of $2.3 Billion, Growing 5%, and Net Income of $581 Million, or $1.29 per Diluted Share, Increasing 11% and 13%, Respectively, on a Reported Basis for Fourth Quarter 2024 Delivers 6% Operational Growth in Revenue and 9% Operational Growth in Adjusted Net Income for Fourth Quarter 2024 Delivers 9% Organic Operational Growth in Revenue for Fourth Quarter 2024 After Accounting for the Divestiture of the Medicated Feed Additive Product Portfolio, Certain... Read more


Telix Pharmaceuticals to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)

MELBOURNE, Australia and INDIANAPOLIS, Feb. 13, 2025 (GLOBE NEWSWIRE) --  Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces presentations featuring the Company’s late-stage and next generation therapeutic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025) to be held in San Francisco, CA (US) from 13 – 15 February 2025. Dr. David N. Cade, Telix Group Chief Medical... Read more


Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater fat loss and improvement of physical function The Independent Data Monitoring Committee met this week on February 10, 2025 to evaluate the unblinded safety Phase 2b QUALITY data and recommended to continue the QUALITY extension study as designed Topline results of the... Read more


Telix Pharmaceuticals: Illuccix Approved in the United Kingdom

MELBOURNE, Australia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET1 imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection). Illuccix is indicated in the UK for the detection and localization... Read more


U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Approval is based on positive data from the Phase 3 ECHELON-3 trial, which demonstrated ADCETRIS regimen reduced the risk of death by 37%, a statistically significant, clinically meaningful improvement in overall survival (OS), compared to lenalidomide and rituximab plus placebo ECHELON-3 is the first Phase 3 trial to demonstrate OS advantage over lenalidomide and rituximab plus placebo for patients with at least 2 prior lines of therapy with R/R diffuse large B-cell... Read more


FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)

Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and safety as the currently available oral solution New tablet formulation may provide greater freedom and independence for people with SMA thanks to simplified dose administration SOUTH SAN FRANCISCO, Calif. / Feb 12, 2025 / Business Wire / Genentech, a member of the Roche... Read more


AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immu... Read more


Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results

Product Sales Excluding Veklury Increased 8% Year-Over-Year to $26.8 billion for Full Year 2024 Biktarvy Sales Increased 13% Year-Over-Year to $13.4 billion for Full Year 2024 Oncology Sales Increased 12% Year-Over-Year to $3.3 billion for Full Year 2024 FOSTER CITY, Calif. / Feb 11, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024. “Gilead delivered another exceptionally... Read more


Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathway Abelacimab is currently in Phase 3 development, with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillation Acquisition adds a late-stage asset and is aligned with Novartis strategic focus, strength and expertise in the cardiovascular therapeutic ar... Read more


Health Canada Approves Merck's KEYTRUDA® (pembrolizumab) for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with...

Approval is based on the Phase 3 KEYNOTE-671 Trial KIRKLAND, QC, Feb. 11, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, as a treatment for adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment,... Read more


Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market

Finalizing scale-up production phase Engaging with Contract Research Organizations to complete the technical dossier Clinical trials expected to complete in late 2025 or early 2026 Potential classification as a Class III medical device Product launch expected in the first or second quarter of 2026 Further updates on progress to follow in the coming months CHICAGO, IL / ACCESS Newswire / February 11, 2025 / Cosmos Health Inc. ("Cosmos Health"... Read more


PetIQ Names Camillo Pane as Chief Executive Officer

Accomplished Consumer Goods and Health Care Leader Would Bring Decades of Leadership Experience to Role EAGLE, Idaho, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”), a leading pet medication, health and wellness company and portfolio company of Bansk Group, is pleased to announce that Camillo Pane would join PetIQ as Chief Executive Officer, effective February 17, 2025. Mr. Pane would succeed Cord Christensen. Mr. Pane’s passion... Read more


Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination as standard of care in first-line treatment of la/mUC At nearly 30 months of follow-up in the Phase 3 EV-302 trial, the combination doubled median overall survival and progression-free survival compared to chemotherapy, with no new safety signals identified NEW YORK & TOKYO / Feb 10, 2025 / Business Wire / Pfizer... Read more


Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market

CHICAGO, IL / ACCESS Newswire / February 10, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the filing of two new patent applications, covering groundbreaking developments in the treatment... Read more


Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

Trial met primary endpoint of overall response rate and key secondary endpoint of complete response rate With these data, Breyanzi demonstrates efficacy and manageable safety in a fifth cancer type, the most of any CD19-directed CAR T cell therapy PRINCETON, N.J. / Feb 10, 2025 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi® (lisocabtagene maraleucel) in adult patients with relapsed or refractory... Read more


Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations

CHICAGO, IL / ACCESS Newswire / February 10, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Dimitris Moraitis as Vice President of Strategy & Operations. Mr.... Read more


AbbVie: U.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options

EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteria Gram-negative bacterial infections represent a significant public health threat due to their ability to develop resistance to antimicrobial therapies Antimicrobial resistance (AMR) could lead to over 39 million deaths worldwide by 2050, and new treatments... Read more


Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog...

CHICAGO, IL / ACCESS Newswire / February 7, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly owned subsidiary, Cana Laboratories ("Cana"), has entered into a new long-term... Read more


Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients ( 3 Years Old)

First data in NPC1 on treatment in this age group over a period of 48 weeks At 24 weeks of the sub-study, 7 of 8 patients (87%) and at 48 weeks of the sub-study, 6 of 7 patients (86%) show stabilization or improvement in Clinical Global Impression – Change (CGI-C) Scale Data presented at the 21st Annual WORLDSymposium™ 2025 Company on track for topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ in H1 2025 GAINESVILLE, Fla.... Read more


Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of patients who achieved endoscopic response at one year sustained it at two years Omvoh is the first IL-23p19 antagonist to demonstrate multi-year, sustained efficacy and safety for both Crohn's disease and ulcerative colitis INDIANAPOLIS, Feb. 7, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced... Read more


New England Journal of Medicine Publishes New Data for Genentech’s Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis

Nearly half of patients on Gazyva plus standard therapy achieved a complete renal response (CRR), with a statistically significant and clinically meaningful improvement, compared to standard treatment alone Analysis showed consistent CRR benefit across patient subgroups highlighting potential to treat a broad patient population with high unmet need Gazyva is the only anti-CD20 monoclonal antibody in a phase III study to demonstrate CRR benefit, which is associated with... Read more


Amgen to Present at the 35th Annual Oppenheimer Healthcare Life Sciences Conference

THOUSAND OAKS, Calif., Feb. 7, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 35th Annual Oppenheimer Healthcare Life Sciences Conference at 11:20 a.m. ET on Wednesday, Feb. 12, 2025. Narimon Honarpour, senior vice president of global development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.  The webcast, as... Read more


Dr. Reddy's Laboratories enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

Dr. Reddy’s gets exclusive rights to commercialize the subcutaneous as well as intravenous formulations of HLX15 in the U.S. and Europe HYDERABAD, India / Feb 06, 2025 / Business Wire / Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy’s”), today announced that it has entered into a license agreement... Read more


Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024

Performance Reflects Progress Toward Delivering Sustained, Top-Tier Growth Fourth Quarter Revenues were $12.3 Billion, Increasing 8% (+9% Adjusting for Foreign Exchange); GAAP Earnings Per Share (EPS) was $0.04 and Non-GAAP EPS was $1.67 Growth Portfolio Revenues were $6.4 Billion, Increasing 21% (+23% Adjusting for Foreign Exchange) Full-Year Revenues were $48.3 Billion, Increasing 7% (+9% Adjusting for Foreign Exchange); GAAP Loss Per Share was $(4.41) and Non-GAAP... Read more


Eli Lilly reports full Q4 2024 financial results and provides 2025 guidance

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline progress included the approval of Zepbound in the U.S. for moderate-to-severe obstructive sleep apnea in adults with obesity and the approval of Omvoh in the U.S. for moderately to severely active Crohn's disease. Notable recent events include the pending acquisition of Scorpion Therapeutics, Inc's... Read more